SCHEMBL1741109

SCHEMBL1741109

CCOC(=O)C(=O)CC(=O)CC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.38
GAA P10253 1/20 0.38
SI P14410 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
EGLN1 Q9GZT9 1/20 0.37
MAPT P10636 1/20 0.36
MMP8 P22894 1/20 0.36
ALDH1A1 P00352 6/20 0.36
NPSR1 Q6W5P4 1/20 0.35
GLO1 Q04760 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
CYP2D6 P10635 1/20 0.35
FAAH O00519 2/20 0.35
POLB P06746 1/20 0.35
LMNA P02545 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TSHR P16473 1/20 0.34
ALOX15 P16050 1/20 0.33
SOAT1 P35610 1/20 0.33
CTDSP1 Q9GZU7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4574752 0.83 ALDH1A1 (0.42) MGAMGAASIMGAM2EGLN1
SCHEMBL17817681 0.83 GAA (0.48) MGAMGAASIMGAM2EGLN1
SCHEMBL21299 0.79 GAA (0.58) MGAMGAASIMGAM2MMP8
SCHEMBL1178944 0.79 MGAM (0.44) MGAMGAASIMGAM2EGLN1
SCHEMBL8804853 0.78 GAA (0.52) MGAMGAASIMGAM2EGLN1
SCHEMBL9582149 0.76 GAA (0.38) MGAMGAASIMGAM2MAPT
SCHEMBL5762176 0.75 ALDH1A1 (0.42) MGAMGAASIMGAM2EGLN1
SCHEMBL28614733 0.75 ALDH1A1 (0.48) MGAMGAASIMGAM2EGLN1
SCHEMBL1179018 0.75 FAAH (0.44) MGAMGAASIMGAM2EGLN1
SCHEMBL141672 0.75 GAA (0.41) MGAMGAASIMGAM2EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors AJAX THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
EP-2390252-A1 New pyrazole derivatives Almirall, S.A. (ES) 2011-11-30 EP disclosed
EP-2390252-A1 New pyrazole derivatives Almirall, S.A. (ES) 2011-11-30 EP disclosed
WO-2011144338-A1 PYRAZOLE DERIVATIVES AS S1P1 AGONISTS ALMIRALL, S.A. (ES) 2011-11-24 WO disclosed
WO-2010043633-A1 2H-PYRAZOLO [4,3-D]PYRIMIDIN-5-AMINE DERIVATIVES AS H4 HISTAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ALLERGIC, IMMUNOLOGICAL AND INFLAMMATORY DISEASES PALAU PHARMA, S. A. (ES) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors JAK2, JAK3, STAT5B MGAM 4511/4885GAA 2648/4885SI 4856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.